| Accession |
PRJCA025546 |
| Title |
Study of TDXd vs Investigator's Choice Chemotherapy in HER2 low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting |
| Relevance |
Medical |
| Data types |
Transcriptome or Gene expression
|
| Organisms |
Homo sapiens
|
| Description |
This is a phase 3 randomized, multi center, open label study. This study is designed to compare T-DXd against investigator's choice single agent chemotherapy to determine if T-DXd can improve outcomes in HR+ HER2 low breast cancer patients whose disease has progressed on at least 2 lines of prior ET in the metastatic setting. |
| Sample scope |
Multiisolate |
| Release date |
2024-04-23 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Astrazeneca
|
|
NA
|
|
|
|
| Submitter |
Xichun
Hu (xchu2009@hotmail.com)
|
| Organization |
Fudan University Shanghai Cancer Center |
| Submission date |
2023-10-23 |
